![](/images/graphics-bg.png)
Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma : A Prospective Multicenter Study
المؤلفون المشاركون
Kim, Seok Jin
Kim, Byung Soo
Park, Joon Seong
Joo, Young Don
Jo, Deog Yeon
Eom, Ki-Seong
Mun, Yeung-Chul
Kwak, Jae-Yong
Yoon, Sung-Soo
Choi, Young Jin
Kang, Hye Jin
Park, Chi-Young
Kim, Jin Seok
Lee, Je-Jung
Min, Chang-Ki
Suh, Cheolwon
Kim, Chul Soo
Kim, Yang Soo
Kim, Sung-Hyun
Kim, Yoo-Jin
المصدر
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-06-23
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
We conducted a prospective multicenter study identifying the role of bortezomib in patients with relapsed or refractory plasma cell myeloma (PCM) in bone resorption and formation via bone turnover markers.
A total of 104 patients received at least 1 cycle of bortezomib.
Most of them had advanced disease (n=89).
Among them, 75 patients completed 4 cycles of treatment.
Most of the patients (81.7%) were treated in combination with steroid.
After the 4th cycle treatment, 47 of 75 patients achieved CR, nCR, VGPR, and PR (64.4%), while 26 patients achieved less than PR (35.6%).
The proportion of patients who achieved ≥ PR increased as patients received more treatment cycles, reaching 90% after the 8th cycle.
DKK-1 levels decreased significantly posttreatment.
Bone formation markers (bALP and OC) and osteoclast regulator such as sRANKL also decreased significantly.
These findings were observed primarily in patients who received steroid and who had a longer disease duration.
While sRANKL demonstrated significant reduction posttreatment, osteoprotegerin (OPG) level did not significantly change posttreatment, resulting in a decreased sRANKL/OPG ratio (P=0.037).
In conclusion, our clinical data suggest that treatment with bortezomib and steroid may rearrange the metabolic balance between osteoblast and osteoclast activities in PCM.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Eom, Ki-Seong& Kim, Seok Jin& Lee, Je-Jung& Suh, Cheolwon& Kim, Jin Seok& Yoon, Sung-Soo…[et al.]. 2014. Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma : A Prospective Multicenter Study. BioMed Research International،Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-456878
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Eom, Ki-Seong…[et al.]. Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma : A Prospective Multicenter Study. BioMed Research International No. 2014 (2014), pp.1-7.
https://search.emarefa.net/detail/BIM-456878
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Eom, Ki-Seong& Kim, Seok Jin& Lee, Je-Jung& Suh, Cheolwon& Kim, Jin Seok& Yoon, Sung-Soo…[et al.]. Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma : A Prospective Multicenter Study. BioMed Research International. 2014. Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-456878
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-456878
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)